{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"75.450","rs_stock_flag":false,"fiscal_year_end":"","hist_closedate":"","replication_method":null,"amt_os":"161,690,510","primaryexch":"香港交易所","ric":"6938.HK","product_subtype":null,"db_updatetime":"2026年1月9日09:36","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BVK63M7","am":"549.86","iv":"","ew_strike":"","as":"70.450","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"70.400","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"200","update_time":"2026-01-09 01:36:34.0","lo52":"","shares_issued_date":"2026年1月9日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"梁子才","underlying_ric":"6938.HK","hi52":"","issuer_name":"蘇州瑞博生物技術股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2026年1月9日10:27","aum_date":"","lo":"65.900","mkt_cap":"11.39","f_aum_hkd":null,"ew_sub_per_to":"","ls":"70.450","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"0","aum":"","issued_shares_class_B":null,"vo":"7.60","secondary_listing_flag":false,"listing_date":"2026年1月9日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"蘇州瑞博生物技術股份有限公司 - B - H股","nm_s":"瑞博生物－Ｂ","sym":"6938","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"蘇州瑞博生物技術股份有限公司是一家主要從事小核酸藥物研究和開發，尤其專注於小干擾核酸（siRNA）療法的中國公司。該公司的主營業務是從事小核酸藥物的創新，專注於心血管、代謝類、腎臟和肝病以及其他治療領域。該公司的藥物管綫包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。該公司主要在中國國內市場開展業務。","op":"75.000","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國江蘇省<br/>昆山市<br/>玉山鎮<br/>元豐路168號","pc":"0.00","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"","isin":"CNE100007DS6","moneyness":""}},"qid":"1767926565414"}
